Genenta Science SpA (NASDAQ: GNTA) — Perfil da empresa, notícias e dados financeiros
Genenta Science SpA develops gene therapy technologies targeting cancer, focusing on delivering targeted treatments.

Genenta Science SpA
Genenta Science SpA ADR (NASDAQ:GNTA) focuses on pioneering gene therapy technologies targeting and defeating cancer. At its core, the company specializes in developing gene transfer strategies to specifically deliver therapeutic effects to cancerous cells while sparing healthy ones, showcasing a promising revolution in oncologic treatments. Their projects, including the development of Temferon, aim to address unmet medical needs in various cancer types, demonstrating a dedication to improving patient outcomes through innovation. Focused on achieving milestones in cancer gene therapy, Genenta's objectives encompass advancing their pipeline products through clinical trials, expanding their research into new therapeutic areas, and ultimately bringing transformative treatments to patients worldwide. Their endeavors are underscored by a commitment to scientific excellence and compassion for those affected by cancer.
Resumo
Operações
Produtos e/ou serviços de Genenta Science SpA
- Temferon: A gene therapy product targeting cancer with an initial focus on glioblastoma, employing patient's own cells modified outside the body.
- Research in CAR-T technologies: Enhancing Chimeric Antigen Receptor T-cells for better targeting and killing of cancer cells.
- Oncolytic virus therapies: Developing viruses that selectively infect and kill cancer cells, while sparing healthy ones.
- Cancer immunotherapy: Creating treatments that boost the immune system's natural ability to fight cancer.
- Gene editing techniques: Exploring CRISPR and other gene editing tools for precise correction of genetic mutations in cancer.
- Stem cell therapy: Investigating the use of stem cells to regenerate damaged tissues and organs in cancer patients.
equipe executiva do Genenta Science SpA
- Pierluigi ParacchiCo-Founder, Chairman, CEO & GM
- Richard B. SlanskyChief Financial Officer
- Gianfranco De NigrisVice President of Corporate Development
- Barbara RegoniniFinance Director
Últimas notícias sobre a Genenta Science SpA
Principais indicadores financeiros
Resultados divulgados pela Genenta Science SpA , em EUR.
- Cap. de mercado
- 29,2 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -0.4
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -6,3 mi | -6,3 mi | |
| 0 | -10,2 mi | -9,3 mi | |
| 0 | -11,5 mi | -11,4 mi | |
| 0 | -10,8 mi | -8,3 mi |